- Home
- SNTG vs DRMA Comparison
SNTG vs DRMA Comparison
Compare SNTG & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTG
- DRMA
- Stock Information
- Founded
- SNTG 2009
- DRMA 2014
- Country
- SNTG China
- DRMA United States
- Employees
- SNTG N/A
- DRMA N/A
- Industry
- SNTG Finance: Consumer Services
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- SNTG Finance
- DRMA Health Care
- Exchange
- SNTG Nasdaq
- DRMA Nasdaq
- Market Cap
- SNTG 4.8M
- DRMA 4.5M
- IPO Year
- SNTG 2021
- DRMA 2021
- Fundamental
- Price
- SNTG $1.84
- DRMA $0.60
- Analyst Decision
- SNTG
- DRMA Strong Buy
- Analyst Count
- SNTG 0
- DRMA 1
- Target Price
- SNTG N/A
- DRMA $3.00
- AVG Volume (30 Days)
- SNTG 6.5K
- DRMA 94.5K
- Earning Date
- SNTG 07-07-2025
- DRMA 08-06-2025
- Dividend Yield
- SNTG N/A
- DRMA N/A
- EPS Growth
- SNTG N/A
- DRMA N/A
- EPS
- SNTG N/A
- DRMA N/A
- Revenue
- SNTG $107,507.00
- DRMA N/A
- Revenue This Year
- SNTG N/A
- DRMA N/A
- Revenue Next Year
- SNTG N/A
- DRMA N/A
- P/E Ratio
- SNTG N/A
- DRMA N/A
- Revenue Growth
- SNTG N/A
- DRMA N/A
- 52 Week Low
- SNTG $1.43
- DRMA $0.57
- 52 Week High
- SNTG $3.97
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- SNTG 54.53
- DRMA 29.24
- Support Level
- SNTG $1.67
- DRMA $0.57
- Resistance Level
- SNTG $1.92
- DRMA $0.63
- Average True Range (ATR)
- SNTG 0.09
- DRMA 0.04
- MACD
- SNTG 0.01
- DRMA -0.01
- Stochastic Oscillator
- SNTG 62.96
- DRMA 11.55
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.